Exactech (NASDAQ: EXAC) is one of 80 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its competitors? We will compare Exactech to related companies based on the strength of its dividends, analyst recommendations, earnings, risk, profitability, institutional ownership and valuation.

Insider & Institutional Ownership

64.6% of Exactech shares are held by institutional investors. Comparatively, 65.5% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 28.3% of Exactech shares are held by insiders. Comparatively, 11.9% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.


This table compares Exactech and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Exactech 0.18% 7.22% 5.84%
Exactech Competitors -126.58% -39.95% -10.87%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Exactech and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exactech 0 3 0 0 2.00
Exactech Competitors 208 1202 2685 86 2.63

Exactech presently has a consensus price target of $42.00, suggesting a potential upside of 0.48%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 6.77%. Given Exactech’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Exactech has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Exactech and its competitors revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Exactech $257.57 million $160,000.00 2,090.00
Exactech Competitors $975.11 million $120.37 million 211.23

Exactech’s competitors have higher revenue and earnings than Exactech. Exactech is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Exactech has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Exactech’s competitors have a beta of 1.04, suggesting that their average share price is 4% more volatile than the S&P 500.


Exactech competitors beat Exactech on 9 of the 13 factors compared.

Exactech Company Profile

Exactech, Inc. develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines. The Company distributes joint replacement systems, including knee, hip, spine and extremity implant systems, and biologic products and services and bone cement materials used in orthopedic surgery and dental procedures. The Exactech Knee System provides solutions for partial, primary and revision total knee arthroplasty. Its hip solutions address the continuum of hip arthroplasty. It manufactures and distributes various products and services designed for the healing and regeneration of bone and soft tissue, including products, which contain human allograft.

Receive News & Stock Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related stocks with our FREE daily email newsletter.